Journal of Substance Abuse Treatment
Volume 39, Issue 2 , Pages 150-156 , September 2010

Perceived drug assignment and treatment outcome in smokers given nicotine patch therapy

Received 2 December 2009 ,Revised 25 March 2010 ,Accepted 3 May 2010.

References 

  1. Dar R, Stronguin F, Etter JF. Assigned versus perceived placebo effects in nicotine replacement therapy for smoking reduction in Swiss smokers. Journal of Consulting and Clinical Psychology. 2005;73:350–353
  2. Fisher S, Greenberg RP. How sound is the double-blind design for evaluating psychotropic drugs?. Journal of Nervous and Mental Disease. 1993;181:345–350
  3. Gottlieb AM, Killen JD, Marlatt GA, Taylor CB. Psychological and pharmacological influences in cigarette smoking withdrawal: Effects of nicotine gum and expectancies on smoking withdrawal symptoms and relapse. Journal of Consulting and Clinical Psychology. 1987;55:606–608
  4. Hall SM, Gorecki JA, Reus VI, Humfleet GL, Muñoz RF. Belief about drug assignment and abstinence in treatment of cigarette smoking using nortriptyline. Nicotine and Tobacco Research. 2007;9:467–471
  5. Hróbjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions. Cochrane Database of Systematic Reviews. 2004;2:CD003974
  6. Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE. Measures of abstinence in clinical trials: Issues and recommendations. Nicotine and Tobacco Research. 2003;5:13–25
  7. Hughes JR, Krahn D. Blindness and the validity of the double-blind procedure. Journal of Clinical Psychopharmacology. 1985;5:138–142
  8. Killen JD, Fortmann SP, Davis L, Varady A. Nicotine patch and self-help video for cigarette smoking cessation. Journal of Consulting and Clinical Psychology. 1997;65:663–672
  9. Killen JD, Fortmann SP, Telch MJ, Newman B. Are heavy smokers different from light smokers? A comparison after 48 hours without cigarettes. Journal of the American Medical Association. 1988;260:1581–1585
  10. Kirsch I, Weixel LJ. Double-blind versus deceptive administration of a placebo. Behavioral Neuroscience. 1988;102:319–323
  11. Mooney M, White T, Hatsukami D. The blind spot in the nicotine replacement therapy literature: Assessment of the double-blind in clinical trials. Addictive Behaviors. 2004;29:673–684
  12. Ossip-Klein DJ, Bigelow G, Parker SR, Curry S, Hall S, Kirkland S. Task Force 1: Classification and assessment of smoking behavior. Proceedings of the National Working Conference on Smoking Relapse, Health Psychology. 1986;5:3–11
  13. Perkins K, Sayette M, Conklin C, Caggiula A. Placebo effects of tobacco smoking and other nicotine intake. Nicotine and Tobacco Research. 2003;5:695–709
  14. Quitkin FM, Rabkin JG, Gerald J, Davis JM, Klein DF. Validity of clinical trials of antidepressants. American Journal of Pyschiatry. 2000;157:327–337
  15. Rabkin JG, Markowitz JS, Stewart J, McGrath P, Harrison W, Quitkin FM, et al. Psychiatry Research. 1986;19:75–86
  16. Radloff LS. The CES-D Scale: A self-report depression scale for research in the general population. Applied Psychological Measurement. 1977;1:385–401
  17. Schnoll RA, Epstein L, Audrain J, Niaura R, Hawk L, Shields PG, et al. Can the blind see? Participant guess about treatment arm assignment may influence outcome in a clinical trial of bupropion for smoking cessation. Journal of Substance Abuse Treatment. 2008;34:234–241
  18. Thomas JL, Guo H, Lynam IM, Powell JN, Okuyemi KS, Bronars CA, et al. The impact of perceived treatment assignment on smoking cessation outcomes among African-American smokers. Journal of General Internal Medicine. 2008;23:1361–1366

PII: S0740-5472(10)00117-0

doi: 10.1016/j.jsat.2010.05.013

Journal of Substance Abuse Treatment
Volume 39, Issue 2 , Pages 150-156 , September 2010

Article Tools

* Image Usage & Resolution